FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247434504> ?p ?o ?g. }

• W2247434504 endingPage "65" @default.
• W2247434504 startingPage "58" @default.
• W2247434504 abstract "Because docetaxel (Taxotere, RP 56976; Rhone-Poulenc Rorer, Antony, France) appeared to be active against breast cancer in phase I trials, we performed this phase II study.Thirty-seven patients with measurable disease were enrolled. Only prior hormone therapy was allowed, as was adjuvant chemotherapy completed > or = 12 months earlier. Docetaxel 100 mg/m2 was administered over 1 hour every 21 days. Diphenhydramine hydrochloride and/or corticosteroid premedication was added after hypersensitivity-like reactions (HSRs) were seen in two of the first six patients. Pharmacokinetic studies were performed during cycle 1 for correlation with toxicity.Thirty-seven patients were assessable. Nineteen (51%) required dose reductions, usually for neutropenic fever. The median nadir WBC count was 1.4 x 10(3)/microL. HSRs were noted in 20 patients (54%). At a median cumulative dose of 297 mg/m2 (range, 99.6 to 424.5 mg/m2), 30 patients (81%) developed fluid retention, for which 11 (30%) subsequently stopped treatment. The first-cycle plasma area under the concentration-time curve (AUC) did not correlate with toxicity, although an ineligible patient with hepatic metastases (pretreatment bilirubin level 1.8 mg/dL) had an elevated AUC and died of toxicity. Responses were seen at all sites. On an intent-to-treat basis, there were two (5%) complete responses (CRs) and 18 (49%) partial responses (PRs). The overall response proportion (CRs plus PRs) was 54% (95% confidence interval, 37% to 71%). The median time to response was 12 weeks (range, 3 to 15) and the median duration was 26 weeks (range, 10 to 58+).Docetaxel is active for metastatic breast cancer. Neutropenia and fluid retention are dose-limiting. The AUC did not predict toxicity, but caution is warranted when treating patients with liver dysfunction. An understanding of the pathophysiology of the fluid retention may facilitate prevention. Frequent HSR may warrant prophylactic premedication." @default.
• W2247434504 created "2016-06-24" @default.
• W2247434504 creator A5002190347 @default.
• W2247434504 creator A5003740335 @default.
• W2247434504 creator A5007393182 @default.
• W2247434504 creator A5011012477 @default.
• W2247434504 creator A5019052988 @default.
• W2247434504 creator A5020083811 @default.
• W2247434504 creator A5029590188 @default.
• W2247434504 creator A5039225060 @default.
• W2247434504 creator A5043292277 @default.
• W2247434504 creator A5051244727 @default.
• W2247434504 creator A5053200909 @default.
• W2247434504 creator A5062128184 @default.
• W2247434504 creator A5075752889 @default.
• W2247434504 creator A5078902632 @default.
• W2247434504 creator A5082279705 @default.
• W2247434504 date "1996-01-01" @default.
• W2247434504 modified "2023-10-16" @default.
• W2247434504 title "Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer." @default.
• W2247434504 cites W1537851643 @default.
• W2247434504 cites W1907962006 @default.
• W2247434504 cites W1940165440 @default.
• W2247434504 cites W1959506700 @default.
• W2247434504 cites W1972010711 @default.
• W2247434504 cites W1978228326 @default.
• W2247434504 cites W2027740621 @default.
• W2247434504 cites W2073533584 @default.
• W2247434504 cites W2077084156 @default.
• W2247434504 cites W2104909849 @default.
• W2247434504 cites W2128848742 @default.
• W2247434504 cites W2138550636 @default.
• W2247434504 cites W2155946383 @default.
• W2247434504 cites W2227235589 @default.
• W2247434504 doi "https://doi.org/10.1200/jco.1996.14.1.58" @default.
• W2247434504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8558221" @default.
• W2247434504 hasPublicationYear "1996" @default.
• W2247434504 type Work @default.
• W2247434504 sameAs 2247434504 @default.
• W2247434504 citedByCount "147" @default.
• W2247434504 countsByYear W22474345042012 @default.
• W2247434504 countsByYear W22474345042013 @default.
• W2247434504 countsByYear W22474345042014 @default.
• W2247434504 countsByYear W22474345042017 @default.
• W2247434504 countsByYear W22474345042019 @default.
• W2247434504 countsByYear W22474345042021 @default.
• W2247434504 countsByYear W22474345042022 @default.
• W2247434504 countsByYear W22474345042023 @default.
• W2247434504 crossrefType "journal-article" @default.
• W2247434504 hasAuthorship W2247434504A5002190347 @default.
• W2247434504 hasAuthorship W2247434504A5003740335 @default.
• W2247434504 hasAuthorship W2247434504A5007393182 @default.
• W2247434504 hasAuthorship W2247434504A5011012477 @default.
• W2247434504 hasAuthorship W2247434504A5019052988 @default.
• W2247434504 hasAuthorship W2247434504A5020083811 @default.
• W2247434504 hasAuthorship W2247434504A5029590188 @default.
• W2247434504 hasAuthorship W2247434504A5039225060 @default.
• W2247434504 hasAuthorship W2247434504A5043292277 @default.
• W2247434504 hasAuthorship W2247434504A5051244727 @default.
• W2247434504 hasAuthorship W2247434504A5053200909 @default.
• W2247434504 hasAuthorship W2247434504A5062128184 @default.
• W2247434504 hasAuthorship W2247434504A5075752889 @default.
• W2247434504 hasAuthorship W2247434504A5078902632 @default.
• W2247434504 hasAuthorship W2247434504A5082279705 @default.
• W2247434504 hasConcept C112705442 @default.
• W2247434504 hasConcept C121608353 @default.
• W2247434504 hasConcept C126322002 @default.
• W2247434504 hasConcept C126894567 @default.
• W2247434504 hasConcept C141071460 @default.
• W2247434504 hasConcept C2775930923 @default.
• W2247434504 hasConcept C2776694085 @default.
• W2247434504 hasConcept C2778300832 @default.
• W2247434504 hasConcept C2781190966 @default.
• W2247434504 hasConcept C29730261 @default.
• W2247434504 hasConcept C31760486 @default.
• W2247434504 hasConcept C530470458 @default.
• W2247434504 hasConcept C71924100 @default.
• W2247434504 hasConcept C90924648 @default.
• W2247434504 hasConceptScore W2247434504C112705442 @default.
• W2247434504 hasConceptScore W2247434504C121608353 @default.
• W2247434504 hasConceptScore W2247434504C126322002 @default.
• W2247434504 hasConceptScore W2247434504C126894567 @default.
• W2247434504 hasConceptScore W2247434504C141071460 @default.
• W2247434504 hasConceptScore W2247434504C2775930923 @default.
• W2247434504 hasConceptScore W2247434504C2776694085 @default.
• W2247434504 hasConceptScore W2247434504C2778300832 @default.
• W2247434504 hasConceptScore W2247434504C2781190966 @default.
• W2247434504 hasConceptScore W2247434504C29730261 @default.
• W2247434504 hasConceptScore W2247434504C31760486 @default.
• W2247434504 hasConceptScore W2247434504C530470458 @default.
• W2247434504 hasConceptScore W2247434504C71924100 @default.
• W2247434504 hasConceptScore W2247434504C90924648 @default.
• W2247434504 hasIssue "1" @default.
• W2247434504 hasLocation W22474345041 @default.
• W2247434504 hasLocation W22474345042 @default.
• W2247434504 hasOpenAccess W2247434504 @default.
• W2247434504 hasPrimaryLocation W22474345041 @default.
• W2247434504 hasRelatedWork W1543516950 @default.

• next